Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by SouthernTierTomon Jul 23, 2021 11:03am
154 Views
Post# 33595902

RE:No words

RE:No wordsoh no "chum"..there are words and rather factual to boot;

Here's a sampling:

CTSO   March 2020 low  $ 4.00.     Currently $ 7.46       + 86%
Tailwinds provided by: recent failed UK studies and the possibility of a new US Trial (Phase 1).  MC = 4.4X Spectral's despite no Active Phase 1 Trial in NA.

ohh..and trades on Nasdaq & promotional

AEMD  March 2020 lo $ 1.28.  Currenlty $ 4.08    + 218%
Tailwiinds provided by: the release of some non-trial results (2 CV patients?), and the bantering around of some hemopurfusion ideas (and the frequent trading of shares). 15M shares o/s - daily volumes peaking at over 250M shares.  MC =22% higher than Spectral's despite no revenues

Ohh...and trades on Nasdaq & promotional


EDT  March 2020 lows .44.  Currently $ .38   - 14.0 %

Tailwinds provided by:
  • Phase 3 B confimatory Trial (with favourable FDA parameters, rules/carryforwards)
  • Baxter ($ 40B USD MC) Distribution Agreement put in place 2020
  • FDA approved companion diagnostic (= precision medicien = the future)
  • De-risked Trial with $ advancements by Baxter of $ 5M USD + $ ? M USD + $ ?M USD +?  for Tigris Trial 
  • FDA approval of SAMI for US
  • partial FDA approval of DIMI for hospital use
  • Health Canada approval of DIMI
  • Hiring of Kellum (world KoL on blood filtration and AKI)
  • Latest Analyst target of over $ 3/sh with implied/stated probabilty of success on PMX of over 75%
  • More recent positive RWE on PMX
  • $ 5B+ market opportunity on the second pony trick (HHD) . Possible full FDA approval next year following a Trial to start this year.
  • $ 18M plus in the bank following recent financing at .425 with as yet undisclosed Mgt. rewards (options? warrants?) for great performance

Ohh..and trades in Canada with limited to no news flow to the US. Daily volume miniscule. 

MM
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse